Business Description
Appili Therapeutics Inc
NAICS : 325412
SIC : 3741
ISIN : CA03783R1073
Share Class Description:
TSX:APLI: Ordinary SharesDescription
Appili Therapeutics Inc is a biopharmaceutical company. The company is engaged in novel antibiotic and anti-infective therapies to help patients suffering from serious infections. Its anti-infective portfolio currently includes major programs namely ATI-2307, ATI-1701, ATI-1503, ATI-1501 and Favipiravir.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.08 | |||||
| Equity-to-Asset | -5 | |||||
| Debt-to-Equity | -0.82 | |||||
| Debt-to-EBITDA | -2.25 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -54.95 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -20.6 | |||||
| 3-Year EBITDA Growth Rate | 23.2 | |||||
| 3-Year EPS without NRI Growth Rate | 21.3 | |||||
| 3-Year FCF Growth Rate | 10.5 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 51.16 | |||||
| 9-Day RSI | 47.92 | |||||
| 14-Day RSI | 47.49 | |||||
| 6-1 Month Momentum % | 14.29 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.46 | |||||
| Quick Ratio | 0.46 | |||||
| Cash Ratio | 0.14 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -37.7 | |||||
| Shareholder Yield % | -60.67 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -330.11 | |||||
| Net Margin % | -464.67 | |||||
| FCF Margin % | -273.89 | |||||
| ROA % | -225.9 | |||||
| ROIC % | -1423.99 | |||||
| ROC (Joel Greenblatt) % | -12760.71 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 3.5 | |||||
| EV-to-EBIT | -3.26 | |||||
| EV-to-EBITDA | -3.27 | |||||
| EV-to-Revenue | 10.14 | |||||
| EV-to-FCF | -3.7 | |||||
| Earnings Yield (Greenblatt) % | -30.67 | |||||
| FCF Yield % | -74.15 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Appili Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil C$) | 1.149 | ||
| EPS (TTM) (C$) | -0.041 | ||
| Beta | 0.58 | ||
| Volatility % | 101.82 | ||
| 14-Day RSI | 47.49 | ||
| 14-Day ATR (C$) | 0.003257 | ||
| 20-Day SMA (C$) | 0.036 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (C$) | 0.025 - 0.08 | ||
| Shares Outstanding (Mil) | 121.27 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Appili Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Appili Therapeutics Inc Stock Events
| Event | Date | Price(C$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Appili Therapeutics Inc Frequently Asked Questions
What is Appili Therapeutics Inc(TSX:APLI)'s stock price today?
The current price of TSX:APLI is C$0.04. The 52 week high of TSX:APLI is C$0.08 and 52 week low is C$0.03.
When is next earnings date of Appili Therapeutics Inc(TSX:APLI)?
The next earnings date of Appili Therapeutics Inc(TSX:APLI) is 2024-05-31 Est..
Does Appili Therapeutics Inc(TSX:APLI) pay dividends? If so, how much?
Appili Therapeutics Inc(TSX:APLI) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers